ARTICLE | Clinical News
ALN-HBV: Phase I/II started
July 18, 2016 7:00 AM UTC
Alnylam began a single-blind, placebo-controlled, dose-escalation, U.K. Phase I/II trial of subcutaneous ALN-HBV. The trial will test single doses in up to 24 healthy volunteers and up to 28 patients ...